Can Gdf-15 Level Predict Progression to Multiple Organ Failure in Patients With Septic Shock
Launched by ANKARA CITY HOSPITAL BILKENT · Feb 3, 2025
Trial Information
Current as of August 19, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is studying whether a substance in the blood called GDF-15 can help predict if patients with septic shock will develop multiple organ failure. Septic shock is a serious condition that occurs when an infection leads to dangerously low blood pressure and can affect multiple organs in the body. The researchers want to find out if measuring GDF-15 levels when patients first arrive in the intensive care unit (ICU) can give doctors important information about how well the patients might do in the future.
To participate in this study, patients need to be over 18 years old and diagnosed with septic shock. However, those with certain severe health issues, like end-stage kidney or liver disease, active cancer, or severe heart problems, cannot join. All participants will continue to receive standard treatments for their condition while the researchers observe their health and track any changes in their organ function. This study is currently not recruiting participants, but it aims to improve understanding of septic shock and help doctors provide better care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients older thab 18 years of age
- • Patients with septic shock
- • Patients without end-stage renal failure (KDIGO G4,G5)
- • Patients without chronic liver disease
- • Patients with New York Heart Association (NYHA) stage 1-2
- • Patients not diagnosed with active cancer
- • Non-pregnant patients
- • Patients without chronic immunodeficiency
- • Patients without chronic inflammatory disease
- Exclusion Criteria:
- • Patients younger than 18 years age
- • Patients not diagnosed with septic shock
- • Patients with end-stage renal failure
- • Patients with chronic liver disease
- • Patients with New York Heart Association (NYHA) stage 3-4
- • Patients diagnosed with active cancer
- • Pregnant patients
- • Patients with chronic immunodeficiency
- • Patients with chronic inflammatory diseases
About Ankara City Hospital Bilkent
Ankara City Hospital Bilkent is a leading healthcare institution in Turkey, dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. Equipped with state-of-the-art facilities and a multidisciplinary team of experienced professionals, the hospital fosters a collaborative environment for conducting rigorous scientific investigations. Its commitment to ethical standards and patient safety ensures that all clinical trials are conducted with the highest level of integrity, ultimately contributing to the development of new therapies and enhancing the quality of care provided to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported